GLP-1 Use Linked to Reduced Breast Cancer Risk in Observational Study
An observational study suggests GLP-1 drug use is associated with a 30-35% lower breast cancer risk, warranting further clinical trials.
Ayla Demirhan ·
A large observational study indicates a reduced incidence of breast cancer among individuals using GLP-1 receptor agonists. The study analyzed electronic health records of over 111,000 females aged 45-80 with a BMI of 25 or higher.
Participants prescribed GLP-1 medications showed approximately 30-35% lower odds of developing breast cancer compared to non-users. This association remained significant even after matching for key risk factors such as age, BMI, breast density, and diabetes status.
While the study suggests a correlation
While the study suggests a correlation, it does not establish causation. Further clinical trials are necessary to determine if GLP-1 drugs directly prevent breast cancer.
The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in JCO Oncology Practice. This research supports the need for additional investigation into GLP-1 drugs as a potential breast cancer prevention strategy.